Tiotropium in Early-Stage Chronic Obstructive Pulmonary Disease

Abstract

Tiotropium resulted in a higher FEV than placebo at 24 months and ameliorated the annual decline in the FEV after bronchodilator use in patients with COPD of GOLD stage 1 or 2. (Funded by Boehringer Ingelheim and others; Tie-COPD ClinicalTrials.gov number, NCT01455129 .).

Chronic obstructive pulmonary disease in China: a nationwide prevalence study

“…28,29 However, findings of a 2-year, multicentre, double-blind, randomised controlled trial in patients with COPD of GOLD stage I or II in China showed a significant and clinically relevant higher FEV 1 in patients assigned tiotropium than in those allocated placebo. 30 Moreover, for the population with at least one risk factor or respiratory symptom, evidence suggests that screening by spirometry has changed management and outcomes related to COPD. 1,29 Even when spirometry is not available, an alternative nine-item discriminant function model-ie, age, sex, BMI, smoking index, wheezing, cough, dyspnoea, living environment, and occupational exposure-for peak expiratory flow measurement as a screening method achieved a sensitivity of 89% and specificity of 82% in a Chinese general population.…”

Tiotropium could provide benefits in the early stage of COPD, but further studies are needed

“…A multicentre randomised trial4 of over 800 Chinese COPD patients with mild to moderate [Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage 1 or 2] disease, whose majority (about 90%) had a modified Medical Research Council (mMRC) dyspnea scale score <2 and a forced expiratory volume in 1 s (FEV 1 ) ≥50% predicted, compared tiotropium 18 µg (419 patients) with a placebo used once daily (422 patients) for 2 years. The difference between groups in the changes from baseline to 24 months in FEV 1 before bronchodilator use was the predetermined primary end point.…”

Chronic obstructive pulmonary disease in non-smokers: An Update

“…Smoking causes 25% of all deaths among men and women between 35-69 years in the United States of America (US) [10]. COPD is a high prevalent disease, with prevalence in people over 40 years of 10.1% worldwide and it will become the third cause of death in the world in 2020 and will become the seventh largest burden in 2030 [11,12]. It is estimated that in 2010 number of COPD globally amounted to 384 million, with 3 million deaths annually.…”

“…In the US, COPD is the second cause of death [14]. Consequently, many of the COPD prevalence studies have been conducted and continue to be carried out mainly in cigarette smokers, and many clinical studies recruit only smokers with at least 10-20 packets-year of exposure to smoking [11,15,16].…”